重组人p53腺病毒注射液联合治疗对鼻咽癌组织中KAI1和CD44 v6表达的影响

Differential expression of KAI1 and CD44 in nasopharyngeal carcinoma before and after Gendicine combined with radiotherapy and chemotherapy treatment

目的探讨重组人p53腺病毒注射液(今又生)联合放化疗对鼻咽癌组织中KAI1和CD44 v6表达的影响,并分析KAI1和CD44 v6表达与鼻咽癌患者预后之间的关系。方法 58例鼻咽癌患者经直线加速器常规放疗和两个阶段铂类+5-Fu的同步化疗后再分为今又生治疗组(29例)和对照组(29例),应用免疫组织化学S-P法检测治疗前后癌组织中KAI1及CD44 v6蛋白的表达情况,比较两组患者的肿瘤消退率及远期生存情况。结果治疗组患者治疗后KAI1表达上调、CD44 v6表达下调,而对照组患者治疗前后比较无明显差异;治疗组局部消退率明显高于对照组;治疗组在3年生存率及远期生存情况同对照组比较无明显差异。结论重组人p53腺病毒注射液治疗可以明显影响鼻咽癌组织中KAI1和CD44 v6的表达,提高肿瘤的局部消退率,但无法有效延长远期生存率。

Objective To study differences in expression of KAI1 and CD44 v6 before and after Gendicine treatment, and to explore the relationship between the expression and the clinical characteristics of patients with nasopharyngeal carcinoma （NPC）, and also the relationship between the expression differences and prognosis. Methods 58 NPC patients were randomly divided into two equal groups （treatment group and control group ）. Expression of KAI1 and CD44 v6 protein in tumor tissue of both groups before and after Gendicine treatment was detected with immunohistochemieal SP method. Tumor regression rate and long-term survival rate between the two groups were compared. Results After treatment, the expression of KAI1 was up-regulated and that of CD44 v6 was down-regulated in the treatment group with statistically significant differences, while the differences in the control group were insignificant. Local tumor regression rate of the treatment group was significantly higher than that of the control group. The 3-year survival rate and long-term survival in two groups did not differ significantly. Conclusion Gendicine therapy can significantly affect the expression of KAI1 and CD44 v6 in nasopharyngeal carcinoma, and increase the local tumor regression rate, but can not prolong the survival rate.